Insiders who reported open-market trades in the last 12 months at the companies Sean Brynjelsen files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Sean Brynjelsen is a corporate insider, tracked as President & CEO, Director of Eton Pharmaceuticals, Inc. (ETON). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Sean Brynjelsen submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Sean Brynjelsen been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($9.91M) across all tracked filings.
Sean Brynjelsen is President & CEO, Director of Eton Pharmaceuticals, Inc. (ETON). 5 SEC Form 4 filings on record, most recently on 20 August 2026. Most recent open-market trade: sold $456K of ETON on 20 August 2026. Lifetime open-market sales: $9.91M.
Recent transactions
9
The latest 9 SEC Form 4 transactions reported by Sean Brynjelsen.
InsiderAlpha's records for Sean Brynjelsen go back to 2026: 5 primary Form 4 filings, an average of 5.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
